Topiramate: Effects on cognition in patients with epilepsy, migraine headache and obesity

Therapeutic Advances in Neurological Disorders

Volumn 6, Issue 4, 2013, Pages 211-227

  Sommer, Barbara R ^a   Mitchell, Erica L ^a   Wroolie, Tonita E ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cognition; epilepsy; migraine; obesity; psychiatric; topiramate

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; ETIRACETAM; FELBAMATE; GABAPENTIN; LORCASERIN; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; TETRAHYDROLIPSTATIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADD ON THERAPY; ALCOHOLISM; ANOREXIA; ATTENTION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BODY WEIGHT; BORDERLINE STATE; BRAIN ISCHEMIA; CLOSED ANGLE GLAUCOMA; COGNITION; COMPLEX PARTIAL SEIZURE; CONTROLLED RELEASE FORMULATION; DIZZINESS; DRIVING ABILITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHASIA; EPILEPSY; FATIGUE; FOCAL EPILEPSY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HUMAN; INSOMNIA; INTRACTABLE EPILEPSY; MIGRAINE; MONOTHERAPY; MOOD; NAUSEA; NEUROPROTECTION; NEUROPSYCHOLOGICAL TEST; NONHUMAN; OBESITY; PARESTHESIA; PATTERN RECOGNITION; PHASE 3 CLINICAL TRIAL (TOPIC); POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REACTION TIME; REVIEW; SEIZURE; SIDE EFFECT; SOCIAL PHOBIA; SPATIAL LEARNING; TRAUMATIC BRAIN INJURY; VERBAL MEMORY; VISUAL MEMORY; WORKING MEMORY;

EID: 84880391918     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285613481257     Document Type: Article

References (121)

1. Aarsen F. van den Akker E. Drop S. Catsman-Berrevoets C. (2006) Effect of topiramate on cognition in obese children. Neurology 67: 1307–1308.
2. Aldenkamp A. Baker G. Mulder O. Chadwick D. Cooper P. Doelman J. et al. (2000) A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 4: 1167–1178.
3. Allison D. Gadde K. Garvey W. Peterson C. Schwiers M. Najarian T. et al. (2012) Controlled-release phentermine / topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity 20: 330–342.
4. Alves O. Doyle A. Clausen T. Gilman C. Bullock R. (2003) Evaluation of topiramate neuroprotective effect in severe TBI using microdyalysis. Ann N Y Acad Sci 993: 25–34.
5. Arif H. Buchsbaum R. Weintraub D. Pierro J. Resor S. Jr Hirsch J. (2009) Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behav 14: 202–209.
6. Arroyo S. Dodson W. Privitera M. Glauser T. Naritoku D. Dlugos D. et al. (2005) Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand 112: 214–222.
7. Astrup A. Caterson I. Zelissen P. Guy-Grand B. Carruba M. Levy B. et al. (2004) Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 12: 1658–1669.
8. Barnes D. Yaffe K. (2011) The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 10: 819–828.
9. Baskin M. Ard J. Franklin F. Allison D. (2005) Prevalence of obesity in the United States. Obes Rev 6: 5–7.
10. Ben-Menachem E. (2008) Is topiramate tops? Epilepsy Curr 8: 60–61.
11. Blum D. Meador K. Biton V. Fakhoury T. Shneker B. Chung S. et al. (2006) Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology 67: 400–406.
12. Bootsma H. Aldenkamp A. Diepman L. Hulsman J. Lambrechts D. Leenen L. et al. (2006) The effect of antiepileptic drugs on cognition: patient perceived cognitive problems of topiramate versus levetiracetam in clinical practice. Epilepsia 47: 24–27.
13. Bootsma H. Coolen F. Aldenkamp A. Arends J. Diepman L. Hulsman J. et al. (2004) Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 5: 380–387.
14. Bootsma H. Ricker L. Diepman L. Gehring J. Hulsman J. Lambrechts D. et al. (2008) Long-term effects of levetiracetam and topiramate in clinical practice: a head-to-head comparison. Seizure 17: 19–26.
15. Bozikas V. Petrikis P. Kourtis A. Youlis P. Karavatos A. (2002) Treatment of acute mania with topiramate in hospitalized patients. Prog Neuropsychopharmacol Biol Psychiatry 26: 1203–1206.
16. Brandes J. (2005) Practical use of topiramate for migraine prevention. Headache 45: S66–S73.
17. Brandes J. Saper J. Diamond M. Couch J. Lewis D. Schmitt J. et al. (2004) Topiramate for migraine prevention: a randomized controlled trial. JAMA 291: 965–973.
18. Bray G. Hollander P. Klein S. Kushner R. Levy B. Fitchet M. et al. (2003) A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 11: 722–733.
19. Calabresi P. Cupini L. Centonze D. Pisani F. Bernardi G. (2003) Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia. Ann Neurol 53: 693–702.
20. Cha B. Silveira D. Liu X. Hu Y. Holmes G. (2002) Effect of topiramate following recurrent and prolonged seizures during early development. Epilepsy Res 51: 217–232.
21. Chengappa K. Rathore D. Levine J. (1999) Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord 1: 42–53.
22. Chung S. Kerls S. Hammer A. Kustra R. (2009) Cognitive effects of lamotrigine versus topiramate as adjunctive therapy in older adults with epilepsy. Neurol Int 1: e6.
23. Cirulli E. Urban T. Marino S. Linney K. Birnbaum A. Depondt C. et al. (2012) Genetic and environmental correlates of topiramate-induced cognitive impairment. Epilepsia 53: e5–e8.
24. Czapinski P. Blaszczyk B. Czuczwar S. (2005) Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 5: 3–14.
25. Czuczwar S. Patsalos P. (2001) The new generation of GABA enhancers. CNS Drugs 15: 339–350.
26. Diener H. Tfelt-Hansen P. Dahlöf C. Láinez M. Sandrini G. Wang S. et al. (2004) Topiramate in migraine prophylaxis – results from a placebo-controlled trial with propranolol as an active control.J Neurol 251: 943–950.
27. Do Prado-Lima P. Perrenoud M. Kristensen C. Cammarota M. Izquierdo I. (2011) Topiramate diminishes fear memory consolidation and extinguishes conditioned fear in rats. J Psychiatry Neurosci 36: 250–255.
28. Edmonds H. Jr Jiang Y. Zhang P. Shank R. (2001) Topiramate as a neuroprotectant in a rat model of global ischemia-induced neurodegeneration. Life Sciences 69: 2265–2277.
29. Faught E. (2007) Topiramate in the treatment of partial and generalized epilepsy. Neuropsychiatr Dis Treat 3: 811–821.
30. Fhager B. Meiri I. Sjögren M. Edman A. (2003) Treatment of aggressive behavior in dementia with the anticonvulsant topiramate: a retrospective pilot study. Int Psychogeriatr 15: 307–309.
31. Frisch C. Kudin A. Elger C. Kunz W. Helmstaedter C. (2007) Amelioration of water maze performance deficits by topiramate applied during pilocarpine-induced status epilepticus is negatively dose-dependent. Epilepsy Res 73: 173–180.
32. Fritz N. Glogau S. Hoffmann J. Rademacher M. Elger C. Helmstaedter C. (2005) Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 6: 373–381.
33. Gadde K. Allison D. Ryan D. Peterson C. Troupin B. Schwiers M. et al. (2011) Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 377: 1341–1352.
34. Garvey W. Ryan D. Look M. Gadde K. Allison D. Peterson C. et al. (2012) Two-year sustained weight loss and metabolic benefits with controlled-release phentermine / topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 95: 297–308.
35. Gensel J. Tovar C. Bresnahan J. Beattie M. (2012) Topiramate treatment is neuroprotective and reduces oligodendrocyte loss after cervical spinal cord injury. PloS ONE 7: e33519.
36. Giannakodimos S. Georgiadis G. Tsounis S. Triantafillou N. Kimiskidis V. Giatas K. et al. (2005) Add-on topiramate in the treatment of refractory partial-onset epilepsy: clinical experience of outpatient epilepsy clinics from 11 general hospitals. Seizure 14: 396–402.
37. Gomer B. Wagner K. Frings L. Saar J. Carius A. Härle M. et al. (2007) The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav 10: 486–494.
38. Gordon A. Logan B. (2006) Topiramate-positive death-investigation and impaired-driving cases in Washington State. J Anal Toxicol 30:599–602.
39. Groselj J. Guerrini R. van Oene J. Lahaye M. Schreiner A. Schwalen S. (2005) Experience with topiramate monotherapy in elderly patients with recent-onset epilepsy. Acta Neurol Scand 112: 144–150.
40. Gualtieri C. Johnson L. (2006) Comparative neurocognitive effects of 5 psychotropic anticonvulsants and lithium. MedGenMed 8: 46.
41. Guille C. Sachs G. (2002) Clinical outcome of adjunctive topiramate treatment in a sample of refractory bipolar patients with comorbid conditions. Prog Neuropsychopharmacol Biol Psychiatry 26: 1035–1039.
42. Hoover R. Motta M. Davis J. Saatman K. Fujimoto S. Thompson H. et al. (2004) Differential effects of the anticonvulsant topiramate on neurobehavioral and histological outcomes following traumatic brain injury in rats. J Neurotrauma 21: 501–512.
43. Huber B. (2002) Effects of topiramate in patients with epilepsy and intellectual deficits. Nervenarzt 73: 525–532.
44. Janowsky D. Kraus J. Barnhill J. Elamir B. Davis J. (2003) Effects of topiramate on aggressive, self-injurious, and disruptive / destructive behaviors in the intellectually disabled: an open-label retrospective study. J Clin Psychopharmacol 23: 500–504.
45. Jansen J. Aldenkamp A. Marian Majoie H. Reijs R. de Krom M. Hofman P. et al. (2006) Functional MRI reveals declined prefrontal cortex activation in patients with epilepsy on topiramate therapy. Epilepsy Behav 9: 181–185.
46. Johannessen L. (2008) Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 22: 27–47.
47. Johnson B. Rosenthal N. Capece J. Wiegand F. Mao L. Beyers K. et al. (2007) Topiramate for treating alcohol dependence. JAMA 298: 1641.
48. Jokeit H. Ebner A. (1999) Long term effects of refractory temporal lobe epilepsy on cognitive abilities: a cross sectional study. J Neurol Neurosurg Psychiatry 67: 44–50.
49. Kanner A. Wuu J. Faught E. Tatum W. IV Fix A. French J. (2003) A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 4: 548–552.
50. Kececi H. Atakay S. (2009) Effects of topiramate on neurophysiological and neuropsychological tests in migraine patients. J Clin Neurosci 16: 1588–1591.
51. Kelly K. Stephen L. Sills G. Brodie M. (2002) Topiramate in patients with learning disability and refractory epilepsy. Epilepsia 43: 399–402.
52. Ketter T. (2010) Antidepressants, anxiolytics, other anticonvulsants, and other medications. In: Ed. Ketter T. (ed.), Handbook of Diagnosis and Treatment of Bipolar Disorder. Washington, DC: American Psychiatric Publishing.
53. Kim S. Lee H. Jung D. Suh C. Park S. (2006) Cognitive effects of low-dose topiramate compared with oxcarbazepine in epilepsy patients.J Clin Neurol 2: 126–133.
54. Kockelmann E. Elger C. Helmstaedter C. (2003) Significant improvement in frontal lobe associated neuropsychological functions after withdrawal of topiramate in epilepsy patients. Epilepsy Res 54: 171–178.
55. Kopelman P. (2007) Health risks associated with overweight and obesity. Obes Rev 8: 13–17.
56. Korean Topiramate Study Group. (2002) Low dose and slow titration of topiramate as adjunctive therapy in refractory partial epilepsies: a multicentre open clinical trial. Seizure 11: 255–260.
57. Kouzounias K. Kimiskidis V. Siozos T. Violaris K. Kostomitsopoulos N. Karayannakos P. et al. (2011) Topiramate promotes neurological recovery in a new model of traumatic brain injury in rats. Neuroscience 183: 171–177.
58. Krymchantowski A. Jevoux C. (2011) Topiramate versus divalproex sodium in the preventive treatment of migraine: a prospective “real-world” study. Headache 51: 554–558.
59. Kudin A. Debska-Vielhaber G. Vielhaber S. Elger C. Kunz W. (2004) The mechanism of neuroprotection by topiramate in an animal model of epilepsy. Epilepsia 45: 1478–1487.
60. Kushner S. Khan A. Lane R. Olson W. (2006) Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord 8: 15–27.
61. Lagae L. (2006) Cognitive side effects of anti-epileptic drugs: the relevance in childhood epilepsy. Seizure 15: 235–241.
62. Lee H. Jung D. Suh C. Kwon S. Park S. (2006) Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: a 1-year follow-up. Epilepsy Behav 8: 736–741.
63. Lee S. Kim S. Kim J. (2000) Protective effect of topiramate against hippocampal neuronal damage after global ischemia in the gerbils. Neurosci Lett 281: 183–186.
64. Lee S. Sziklas V. Andermann F. Farnham S. Risse G. Gustafson M. et al. (2003) The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia 44: 339–347.
65. Lhatoo S. Wong I. Sander J. (2000) Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy. Epilepsia 41: 338–341.
66. Likhitsathian S. Saengcharnchai P. Uttawichai K. Yingwiwattanapong J. Wittayanookulluk A. Srisurapanont M. (2012) Cognitive changes in topiramate-treated patients with alcoholism: a 12-week prospective study in patients recently detoxified. Psychiatry Clin Neurosci 66: 235–241.
67. Loew T. Nickel M. Muehlbacher M. Kaplan P. Nickel C. Kettler C. et al. (2006) Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study.J Clin Psychopharmacol 26: 61–66.
68. Loring D. Williamson D. Meador K. Wiegand F. Hulihan J. (2011) Topiramate dose effects on cognition: a randomized double-blind study. Neurology 76: 131–137.
69. Luykx J. Mason M. Ferrari M. Carpay J. (2009) Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clin Pharmacol Ther 85: 283–288.
70. Marcotte D. (1998) Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord 50: 245–251.
71. Marino S. Meador K. Loring D. Okun M. Fernandez H. Fessler A. et al. (2009) Subjective perception of cognition is related to mood and not performance. Epilepsy Behav 14: 459–464.
72. Martin R. Kuzniecky R. Ho S. Hetherington H. Pan J. Sinclair K. et al. (1999) Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 52: 321–327.
73. Martins de Lima M. Presti-Torres J. Dornelles A. Bromberg E. Schroder N. (2007) Differential effects of low and high doses of topiramate on consolidation and retrieval of novel object recognition memory in rats. Epilepsy Behav 10: 32–37.
74. McDaniel W. Sawitsky A. Vick K. (2007) Topiramate attenuates a transient learning deficit after lesions inducing intracerebral hemorrhage. Psychol Rep 100: 164–166.
75. McElroy S. Hudson J. Capece J. Beyers K. Fisher A. Rosenthal N. (2007) Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry 61: 1039–1048.
76. McElroy S. Suppes T. Keck P. Jr Frye M. Denicoff K. Altshuler L. et al. (2000) Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 47: 1025–1033.
77. McIntyre R. Mancini D. McCann S. Srinivasan J. Sagman D. Kennedy S. (2002) Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 4: 207–213.
78. Meador K. Loring D. Hulihan J. Kamin M. Karim R. (2003) Differential cognitive and behavioral effects of topiramate and valproate. Neurology 60: 1483–1488.
79. Meador K. Loring D. Vahle V. Ray P. Werz M. Fessler A. et al. (2005) Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology 64: 2108–2114.
80. Mecarelli O. Piacenti A. Pulitano P. Vicenzini E. Rizzo C. Rinalduzzi S. et al. (2001) Clinical and electroencephalographic effects of topiramate in patients with epilepsy and healthy volunteers. Clin Neuropharmacol 24: 284–289.
81. Mikati M. Daderian R. Zeinieh M. Leonard A. Azzam D. Kurdia R. (2011) Potential neuroprotective effects of continuous topiramate therapy in the developing brain. Epilepsy Behav 20: 597–601.
82. Mills K. Drazkowski J. Hammer A. Caldwell P. Kustra R. Blum D. (2008) Relative influences of adjunctive topiramate and adjunctive lamotrigine on scanning and the effective field of view. Epilepsy Res 78: 140–146.
83. Motamedi G. Meador K. (2003) Epilepsy and cognition. Epilepsy Behav 2: 25–38.
84. Mula M. Trimble M. Thompson P. Sander J. (2003) Topiramate and word-finding difficulties in patients with epilepsy. Neurology 60: 1104–1107.
85. Nickel C. Lahmann C. Tritt K. Muehlbacher M. Kaplan P. Kettler C. et al. (2005) Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized, double-blind, placebo-controlled study. J Affect Disord 87: 243–252.
86. Niebauer M. Gruenthal M. (1999) Topiramate reduces neuronal injury after experimental status epilepticus. Brain Res 837: 263–269.
87. Noh M. Kim S. Sun W. Park S. Choi H. Lim J. et al. (2006) Neuroprotective effect of topiramate on hypoxic ischemic brain injury in neonatal rats. Exp Neurol 201: 470–478.
88. Ojemann L. Ojemann G. Dodrill C. Crawford C. Holmes M. Dudley D. (2001) Language disturbances as side effects of topiramate and zonisamide therapy. Epilepsy Behav 2: 579–584.
89. Pandina G. Ness S. Polverejan E. Yuen E. Eerdekens M. Bilder R. et al. (2010) Cognitive effects of topiramate in migraine patients aged 12 through 17 years. Pediatr Neurol 42: 187–195.
90. Ramsay R. Uthman B. Pryor F. Rowan A. Bainbridge J. Spitz M. et al. (2008) Topiramate in older patients with partial-onset seizures: a pilot double-blind, dose-comparison study. Epilepsia 49: 1180–1185.
91. Romigi A. Cervellino A. Marciani M. Izzi F. Massoud R. Corona M. et al. (2008) Cognitive and psychiatric effects of topiramate monotherapy in migraine treatment: an open study. Eur J Neurol 15: 190–195.
92. Rorsman I. Källen K. (2001) Recovery of cognitive and emotional functioning following withdrawal of topiramate maintenance therapy. Seizure 10: 592–595.
93. Salinas-Estabane R. (2002) Topiramate monotherapy in adults with newly diagnosed epilepsy. Adv Ther 19: 126–128.
94. Salinsky M. Storzbach D. Spencer D. Oken B. Landry T. Dodrill C. (2005) Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers. Neurology 64: 792–798.
95. Schubert S. Brandl U. Brodhun M. Ulrich C. Spaltmann J. Fiedler N. et al. (2005) Neuroprotective effects of topiramate after hypoxia-ischemia in newborn piglets. Brain Res 1058: 129–136.
96. Shank R. Gardocki J. Streeter A. Maryanoff B. (2000) An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 41: 3–9.
97. Shannon H. Love P. (2004) Effects of antiepileptic drugs on working memory as assessed by spatial alternation performance in rats. Epilepsy Behav 5: 857–865.
98. Shannon H. Love P. (2005) Effects of antiepileptic drugs on attention as assessed by a five-choice serial reaction time task in rats. Epilepsy Behav 7: 620–628.
99. Shannon H. Love P. (2007) Effects of antiepileptic drugs on learning as assessed by a repeated acquisition of response sequences task in rats. Epilepsy Behav 10: 16–25.
100. Shatskikh T. Zhao Q. Zhou J. Holmes G. (2009) Effect of topiramate on cognitive function and single units from hippocampal place cells following status epilepticus. Epilepsy Behav 14: 40–47.
101. Silberstein S. Neto W. Schmitt J. Jacobs D. (2004) Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 61: 490–495.
102. Singh B. White-Scott S. (2002) Role of topiramate in adults with intractable epilepsy, mental retardation, and developmental disabilities. Seizure 11: 47–50.
103. Sommer B. Fenn H. (2010) Review of topiramate for the treatment of epilepsy in elderly patients. Clin Interv Aging 5: 89–99.
104. Stefan H. Hubbertz L. Peglau I. Berrouschot J. Kasper B. Schreiner A. et al. (2008) Epilepsy outcomes in elderly treated with topiramate. Acta Neurol Scand 118: 164–174.
105. Sturm R. Hattori A. (2012) Morbid obesity rates continue to rise rapidly in the United States. Int J Obes (Lond): DOI: 10.1038/ijo.2012.159. [Epub ahead of print 18 September 2012]
106. Suppes T. (2002) Review of the use of topiramate for treatment of bipolar disorders. J Clin Psychopharmacol 22: 599–609.
107. Szaflarski J. Allendorfer J. (2012) Topiramate and its effect on fMRI of language in patients with right or left temporal lobe epilepsy. Epilepsy Behav 24: 74–80.
108. Thompson P. Baxendale S. Duncan J. Sander J. (2000) Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 69: 636–641.
109. Tonstad S. Tykarski A. Weissgarten J. Ivleva A. Levy B. Kumar A. et al. (2005) Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol 96: 243–251.
110. Trojnar M. Małek R. Chros'cin'ska M. Nowak S. Baszczyk B. Czuczwar S. (2002) Neuroprotective effects of antiepileptic drugs. Pol J Pharmacol 54: 557–566.
111. Vajda F. (2002) Neuroprotection and neurodegenerative disease. J Clin Neurosci 9: 4–8.
112. van Passel L. Arif H. Hirsch L. (2006) Topiramate for the treatment of epilepsy and other nervous system disorders. Expert Rev Neurother 6: 19–31.
113. Vasudev K. Macritchie K. Geddes J. Watson S. Young A. (2006) Topiramate for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev 1: CD003384.
114. Vieta E. Torrent C. Garcia-Ribas G. Gilabert A. Garcia-Parés G. Rodriguez A. et al. (2002) Use of topiramate in treatment-resistant bipolar spectrum disorders. J Clin Psychopharmacol 22: 431–435.
115. VIVUS Inc. (2012) Qsymia Prescribing Information. [Available at: http://www.qsymia.com/pdf/full-prescribing-information.pdf; accessed 13 October 2012]
116. Werz M. Schoenberg M. Meador K. Loring D. Ray P. Kaul-Gupta R. et al. (2006) Subjective preference for lamotrigine or topiramate in healthy volunteers: relationship to cognitive and behavioral functioning. Epilepsy Behav 8: 181–191.
117. Wilding J. van Gaal L. Rissanen A. Vercruysse F. Fitchet M. (2004) A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes (Lond) 28: 1399–1410.
118. Witt J. Elger C. Helmstaedter C. (2012) Impaired verbal fluency under topiramate – evidence for synergistic negative effects of epilepsy, topiramate, and polytherapy. Eur J Neurol: DOI: 10.1111/j.1468–1331.2012.03814.x. [Epub ahead of print 25 June 2012]
119. Yang Y. Li Q. Shuaib A. (2000) Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate. Neuropharmacology 39: 881–888.
120. Yen M. Ewald M. (2012) Toxicity of weight loss agents. J Med Toxicol 8: 145–152.
121. Zhao Q. Hu Y. Holmes G. (2005) Effect of topiramate on cognitive function and activity level following neonatal seizures. Epilepsy Behav 6: 529–536.